Figure 1.

Antitumor effects of drug combinations in mutant KRAS cells.

Notes: H358 (A, C) and PLC/PRF5 (B, D) cells were treated for 96 hours with increasing concentrations of gefitinib and vorinostat (A, B), or sorafenib and vorinostat (C, D). A549 cells were treated with 3 µmol/L gefitinib and/or 2 µmol/L vorinostat and/or 3 µmol/L sorafenib as indicated (E, F). Cell viability was measured by the MTT assay. Values are the means ± standard deviation of three independent experiments. *P<0.05 compared to cells treated with each drug alone.

Abbreviations: CI, combination index; DRI, dose reduction index; Fa, fraction affected.